Dasatinib
is a targeted therapy used to treat certain cases of chronic myelogenous leukemia and acute lymphoblastic leukemia. Specifically it is used to treat cases that are Philadelphia chromosome-positive
302964-02-9:
302964-02-9:
302964-02-9:
302964-02-9:
302964-02-9:
Specifications:
| Intermediate | CAS No’s | API/End Use | Status | Purity |
| 2-(N-BOC)-Aminothiazole-5-carboxylic acid | 302964-02-9 | Dasatinib | Commercial | NLT 98% |
| (E) -N-(2-Chloro-6-Methyl Phenyl)-3-Ethoxy Acrylamide | 863127-76-8 | Dasatinib | Commercial | NLT 98% |
| 2-Amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide | 302964-24-5 | Dasatinib | Pilot Scale | NLT 98% |
| N-(2-Chloro-6-methylphenyl)-2-[(6-chloro-2-methyl-4-pyrimidinyl)amino]-5-thiazolecarboxamide | 302964-08-5 | Dasatinib | Lab Scale | |
| 4,6-dichloro-2-methylpyrimidine | 1780-26-3 | Dasatinib | Commercial | NLT 98% |